NT-proBNP: Laboratory Interference and Clinical Significance

What is NT-proBNP?

1. Analytical Interferences

A. Cross-Reactants in the Immunoassay

Glycosylated NT-proBNP — glycosylation at threonine-71 can reduce antibody affinity for the fragment, affecting assay performance. With chronic HF, glycosylation is more prominent, and this reduces conversion efficiency of proBNP to active BNP and NT-proBNP, complicating interpretation.

• Split products of NT-proBNP's N-terminal portion — the antibodies may cross-react with degradation fragments
• proBNP itself — the intact prohormone may be partially detected by NT-proBNP assay antibodies, especially where conversion to mature peptides is incomplete

B. Heterophilic Antibodies and Rheumatoid Factor

• Heterophilic antibodies (human anti-animal immunoglobulins) — can bridge capture and detection antibodies non-specifically
• Rheumatoid factor (RF) — can interfere through similar bridging mechanisms

C. Nesiritide (Recombinant BNP)

2. Preanalytical Interferences

3. Biological/Clinical Factors That Alter NT-proBNP (Non-Disease Related)

Factors That Raise NT-proBNP

Factors That Lower NT-proBNP

4. Clinical Significance and Decision Cutoffs

Diagnosis of Acute Heart Failure (Rule-Out / Rule-In)

• The 300 pg/mL threshold for ruling OUT HF is age-, sex-, and eGFR-independent
• For ruling IN HF, the age-stratified thresholds are required

Biological Variability (Critical for Serial Monitoring)

• A reference change value (RCV) of ~80% is required before a serial change is considered clinically significant
• Many clinical trials use only a 30% change threshold — this is analytically insufficient and may lead to misinterpretation
• Less than 50% of serial concentrations will exceed expected biological variability within 2 weeks, meaning frequent monitoring is often overused

IFCC C-CB Key Laboratory Recommendations

1. Do not switch assays between patient measurements — different assays are not interchangeable and will yield different concentrations
2. Target analytical CV < 10% for acceptable assay imprecision
3. Apply age- and sex-stratified reference limits
4. Always account for comorbidities (CKD, obesity, AF) when interpreting results
5. Standardization of NT-proBNP assays is still lacking — glycosylation differences affect what is actually measured

5. Non-Cardiac Causes of Elevated NT-proBNP (Box 48.5 — Tietz)

1. Acute or chronic systolic or diastolic heart failure
2. Left ventricular hypertrophy
3. Inflammatory cardiac disease (myocarditis, pericarditis)
4. Systemic hypertension with LVH
5. Pulmonary hypertension
6. Acute or chronic renal failure
7. Ascitic liver cirrhosis
8. Endocrine disorders (hyperaldosteronism, Cushing syndrome)
9. Sepsis

Summary Table

Albumin: Significance and Hypoalbuminemia

1. What is Albumin?

• Total serum protein: 6.0–7.8 g/dL, of which ≥60% should be albumin

2. Physiological Significance of Albumin

A. Maintenance of Plasma Oncotic Pressure

B. Transport / Carrier Protein

C. Amino Acid Reservoir

D. Antioxidant Role

E. Regulation of Its Own Synthesis

3. Causes of Hypoalbuminemia

Decreased Synthesis

• Liver disease (cirrhosis, fulminant hepatic failure) — most common cause; hepatocytes lose synthetic capacity
• Protein-calorie malnutrition / malabsorption — inadequate amino acid substrate
• Chronic inflammation — IL-6 and other cytokines divert hepatic synthetic capacity toward acute-phase proteins

Increased Loss

Dilutional

• IV fluid administration
• Pregnancy (physiological)
• Overhydration

4. Symptoms and Clinical Manifestations of Hypoalbuminemia

A. Edema (Cardinal Sign)

• Peripheral pitting edema — dependent, bilateral (ankles, legs)
• Ascites — especially when combined with portal hypertension in cirrhosis (↑ hydrostatic + ↓ oncotic pressure)
• Pleural effusions
• Pulmonary edema (severe cases)
• Anasarca — generalized body edema in severe hypoalbuminemia

B. Consequences of Impaired Drug Binding

• Higher free drug concentration → risk of drug toxicity despite "normal" total drug levels
• Drugs particularly affected: phenytoin, warfarin, diazepam, prednisolone, furosemide, valproate
• Furosemide resistance in nephrotic syndrome — hypoalbuminemia reduces delivery of the drug to its tubular site of action
• Calcium correction is critical: measured serum calcium falls ~0.8 mg/dL for every 1 g/dL drop in albumin (corrected Ca = measured Ca + 0.8 × [4 − albumin g/dL])

C. Consequences of Impaired Transport

D. Nutritional / Immune Consequences

• Muscle wasting and weakness — amino acid reservoir depleted
• Impaired wound healing
• Susceptibility to infection — if associated with malnutrition or loss of immunoglobulins

E. Prognostic Significance

• Hypoalbuminemia is one of the strongest independent prognostic markers in critically ill patients and those with cirrhosis
• In liver disease, it is a key component of the Child-Pugh score (prognostic scoring for cirrhosis)
• In acute heart failure in elderly patients: higher albumin is associated with decreased 180-day mortality
• Post-surgical hypoalbuminemia that develops rapidly is an ominous prognostic finding

5. Laboratory Significance

6. Conditions That Commonly Present with Hypoalbuminemia

1. Liver cirrhosis (alcoholic, viral, autoimmune)
2. Nephrotic syndrome
3. Protein-losing enteropathy (Crohn's, coeliac disease)
4. Severe malnutrition / cachexia
5. Burns
6. Sepsis / critical illness
7. Advanced malignancy
8. Rheumatoid arthritis and chronic inflammatory states
9. Post-surgical / post-operative state
10. Congestive heart failure (chronic)

• Henry's Clinical Diagnosis and Management by Laboratory Methods, Chapter 20 (Proteins), pp. 327–329
• Brenner and Rector's The Kidney, Chapter 30 (Consequences of Hypoalbuminemia), pp. 1313–1315
• Robbins, Cotran & Kumar Pathologic Basis of Disease, Chapter 4 (Edema / Reduced Osmotic Pressure), p. 120
• Goldman-Cecil Medicine, Hypoalbuminemia section, p. 1071
• Tietz Textbook of Laboratory Medicine, 7th Edition